u/nadia_bakker

Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.

Correction: that is the combination programme, not the monotherapy readout.

Agreed, and the combination arms are where the interesting numbers actually live.

Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.

Careful. A four-week stall is inside normal variation and treating it as failure is how people escalate for no reason.

pack sizes differ, so per-month comparisons need care

vito_chowdhury is right about cross-border recognition being narrower than the summaries suggest.

injection-site soreness made the first fortnight rough at each step up, then flattened out. Predictable enough that I started planning around it.

Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.

Careful with the mechanism claim. Glucagon agonism is plausible as an explanation and it has not been isolated as the operative one.

dose day drift of a day either way is fine, the curve barely notices

What does the tolerability table say at that dose?

Has anyone posted an independent purity result for this compound?

What did week 47 look like compared with this one? The month either side is the useful comparison.

Receptor expression in a tissue is necessary but not sufficient for an effect.

Agreed — and it is why the central and peripheral stories are complementary rather than rival.

Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.

Adding the caveat the paper itself makes in its limitations section, which is stronger than anything in this thread.

Disagreeing with this specific inference — that is a preclinical result being read as human pharmacology.

the ladder exists because the gut needs the time, not because the pharmacy likes paperwork

The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.

mechanism explains a direction, not a magnitude

Agreed — and it is why the central and peripheral stories are complementary rather than rival.

How long was the stall before you decided it was a stall?

Careful. A four-week stall is inside normal variation and treating it as failure is how people escalate for no reason.

Are you comparing against a GLP-1 monotherapy result? They are not comparable.

a mechanism you can state is not a mechanism you have demonstrated

Which receptor family are you attributing that effect to?

staying at 0.25mg for an extra month is a legitimate plan

staying at 0.5mg for an extra month is a legitimate plan

I would push back gently. Going up because the scale paused is the single most common mistake described on this board.